Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pyrifol-M is an oral combination vitamin product developed by Solis Pharma, containing the biologically active forms of vitamins B9 (levomefolate), B12 (methylcobalamin), and B6 (pyridoxal 5-phosphate). Unlike synthetic folic acid or pyridoxine, these coenzymated forms do not require extensive metabolic conversion, making them highly effective for individuals with enzymatic deficiencies. The formulation is primarily indicated for the management of nutritional deficiencies and hyperhomocysteinemia, and it is frequently used to support neurological health in conditions such as diabetic peripheral neuropathy. Levomefolate facilitates DNA synthesis and the remethylation of homocysteine to methionine, while methylcobalamin serves as an essential cofactor for methionine synthase. Pyridoxal 5-phosphate acts as a coenzyme for numerous enzymatic reactions, including the transsulfuration pathway that further regulates homocysteine levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levomefolate + methylcobalamin + pyridoxal 5-phosphate.